Ingeneious
Ingeneious #4 2020, News from CombiGene
Ingeneious 2020 2021 2020 2019 2018 2017 Read CombiGene´s newsletter Ingeneious in EnglishTo Ingeneious >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through...
read moreIngeneious #3 2020, News from CombiGene
Ingeneious 2020 2021 2020 2019 2018 2017 Read CombiGene´s newsletter Ingeneious in EnglishTo Ingeneious >> 2021 » News » Regulatory news » Financial reports » Interviews and presentations » Ingeneious 2020 » News » Regulatory news » Financial reports...
read moreIngeneious #2 2020, News from CombiGene
Ingeneious #1 2020, News from CombiGene
Ingeneious #4 2019, News from CombiGene
Ingeneious #3 2019, News from CombiGene
Ingeneious #2 2019, News from CombiGene
Ingeneious #1 2019, News from CombiGene
Ingeneious #5 2018, News from CombiGene
Ingeneious #4 2018, News from CombiGene
Find it easy
Presscontact
» press@combigene.com
Press & financial reports
» Pressreleases (MAR) and Financial reports
News
» News
» Ingenious
» Calendar
» Videopresentations
Downloads
» Images
» Logotypes
Newsletter
"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
About CombiGene
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden